Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (KBLB) has filed for an expanded investment license for Prodigy Silk to support further spider silk production growth. The company plans to use additional capital for new capacity, infrastructure and higher output.
In April 2026, production reached five times its previous high. In June, production reached nearly 2.5 metric tons of spider silk cocoons in a single cycle; August output exceeded that level by more than 30%. Three rearing centers now operate in parallel, supported by expanded mulberry cultivation. Kraig Labs also shipped its first custom spider silk yarn for a performance sportswear application.
Kraig Biocraft Laboratories (OTCQB: KBLB) is running its September/October production cycle across all three centers following its first performance sportswear delivery. The company fulfilled that purchase order by shipping custom recombinant spider silk yarn to a globally recognized brand. Early reports indicate the current rearing cycle remains on track; it is not yet complete.
The centers use staggered schedules to maintain a steady supply of hybrid silkworm eggs for subsequent silk production and reduce reliance on a single facility. The current cycle focuses on parental strains, the breeding lines used to produce those eggs. Silk production grew more than 30% through the rainy season in the last production run. Management believes the phased production model helped deliver that result and positions operations to address additional commercial orders.
Kraig Biocraft Laboratories (KBLB) shipped its first commercial order of recombinant spider silk yarn to a performance sports brand. The small, confidential pilot shipment was made to the customer's specifications for development into a performance textile. Customer validation and product integration remain ahead; the shipment does not establish recurring revenue or broad commercial adoption.
Kraig previously reported producing more than 1.3 metric tons of spider silk cocoons in a single month earlier in 2026. It also recently completed the functional, living Atlas Gene Library under Project Atlas. The company intends to use the library to develop fibers with tailored properties for different applications. Uses beyond apparel remain development opportunities rather than established commercial markets for Kraig.
Kraig Biocraft Laboratories (KBLB) shipped its first commercial order of recombinant spider silk yarn for a performance sports brand. The yarn was custom-processed to the customer's specifications and shipped to fulfill a purchase commitment under a confidential pilot development program. The shipment is small by design, and the yarn is slated for development into a performance textile.
Kraig Biocraft Laboratories (KBLB) completed its Atlas Gene Library by integrating every planned Project Atlas transgene into living commercial silkworm hosts.
The library enables more than 200 potential genetic configurations, which remain designs to investigate rather than tested fibers. Kraig aims to combine the full Atlas suite in one production strain and pursue greater strength, toughness and flexibility than its current spider silk production line. Testing will determine the properties of Atlas-derived fibers; the targeted performance has not yet been demonstrated.
Kraig Biocraft Laboratories (KBLB) completed its Project Atlas Gene Library by integrating every planned transgene into living commercial silkworm hosts. The company has entered the next phase of developing stable homozygous breeding lines for each transgene.
Those lines are intended to support the creation and evaluation of more than 200 potential genetic pairing configurations. Kraig plans to study how the technologies perform together and identify combinations for further development. Its ultimate objective is to combine the full suite of Atlas genes in a single production strain.
Kraig Biocraft Laboratories (KBLB) outlined its progress in scaling recombinant spider silk production as New York Fashion Week begins.
The company links growing fashion-industry interest in bio-based and innovative textiles to its spider silk fibers, produced by genetically engineered silkworms rather than fermentation and post-processing. Kraig Labs reported producing approximately 3.2 metric tons of recombinant spider silk cocoons in a single production cycle earlier this year, described as a world record, and expects higher volumes. The production model is designed to use existing global silk infrastructure for potential luxury, performance apparel, protective and other advanced-material applications. Kraig Labs’ biomaterials work was also featured on the cover of the March 2026 issue of National Geographic.
Kraig Biocraft Laboratories (KBLB) highlighted a recent Tech Times feature that examines the scientific basis and commercialization path of its recombinant spider silk platform. The article explains how Kraig Labs uses genetically engineered Bombyx mori silkworms as biological production systems, leveraging their existing silk glands to spin spider silk proteins at scale. Kraig Labs recently reported a new production record on August 24, 2026, lifting output by more than 30% over its prior milestone, achieved during the technically challenging rainy season. The company positions this as evidence that its silkworm-based platform can move spider silk from science fiction toward commercial reality. Its work in scaling spider silk production was also featured on the cover of the March 2026 issue of National Geographic.
Kraig Biocraft Laboratories (OTCQB: KBLB) reported a new record for recombinant spider silk production, increasing output by more than 30% versus its prior record cycle. This growth was achieved during the rainy season, which the company describes as the most technically challenging period for sericulture due to environmental instability and mulberry handling issues.
Kraig Labs managed the cycle under a constraint of limited usable mulberry leaves and stated that rearing capacity could have supported even higher output with more feedstock. The company is securing additional land to expand in-house mulberry production, targeting new capacity within two to three months. Management also highlighted a shift from batch to continuous rolling production, aiming to support commercial-scale spider silk supply in all seasons.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that CEO and founder Kim Thompson authored a thought leadership editorial in Biocompare titled “Beyond Therapeutics: The Next Chapter of Synthetic Biology Is Manufacturing.” According to Kraig Biocraft Laboratories, the article introduces an “authored biology” framework, emphasizing enhancing proven natural systems, such as engineered silkworms, to produce recombinant spider silk at commercial scale.
The piece contrasts lab protein production with full-scale manufacturing and argues that synthetic biology’s next phase will be defined by consistent, economical, large-scale production. The company notes this perspective reflects its multi‑year effort to scale spider silk and supports its positioning in biology-enabled manufacturing and biomaterials, recently highlighted in a March 2026 National Geographic cover feature.